- Home
- GENK vs IGC Comparison
GENK vs IGC Comparison
Compare GENK & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENK
- IGC
- Stock Information
- Founded
- GENK 2011
- IGC 2005
- Country
- GENK United States
- IGC United States
- Employees
- GENK N/A
- IGC N/A
- Industry
- GENK Restaurants
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- GENK Consumer Discretionary
- IGC Health Care
- Exchange
- GENK Nasdaq
- IGC Nasdaq
- Market Cap
- GENK 16.3M
- IGC 39.8M
- IPO Year
- GENK 2023
- IGC N/A
- Fundamental
- Price
- GENK $3.12
- IGC $0.41
- Analyst Decision
- GENK Strong Buy
- IGC Strong Buy
- Analyst Count
- GENK 2
- IGC 2
- Target Price
- GENK $7.00
- IGC $4.00
- AVG Volume (30 Days)
- GENK 55.3K
- IGC 1.3M
- Earning Date
- GENK 11-11-2025
- IGC 11-11-2025
- Dividend Yield
- GENK 3.73%
- IGC N/A
- EPS Growth
- GENK N/A
- IGC N/A
- EPS
- GENK N/A
- IGC N/A
- Revenue
- GENK $216,137,000.00
- IGC $1,327,000.00
- Revenue This Year
- GENK $12.35
- IGC $15.26
- Revenue Next Year
- GENK $14.62
- IGC $3.41
- P/E Ratio
- GENK N/A
- IGC N/A
- Revenue Growth
- GENK 10.67
- IGC 24.95
- 52 Week Low
- GENK $3.03
- IGC $0.25
- 52 Week High
- GENK $10.33
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- GENK 40.06
- IGC 51.81
- Support Level
- GENK $3.11
- IGC $0.38
- Resistance Level
- GENK $3.39
- IGC $0.44
- Average True Range (ATR)
- GENK 0.15
- IGC 0.03
- MACD
- GENK 0.02
- IGC -0.00
- Stochastic Oscillator
- GENK 25.00
- IGC 32.33
About GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. It operates 43 Gen Korean BBQ restaurants in the United States.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.